Welcome to our dedicated page for STEMTECH news (Ticker: STEK), a resource for investors and traders seeking the latest updates and insights on STEMTECH stock.
Stemtech Corporation (STEK) develops and distributes stem cell nutrition and stemceutical wellness products, including plant-based nutritional supplements, skin care and oral care products. Its updates commonly cover product availability, inventory funding, the Stemtech BioSciences e-commerce retail channel, and the company's network marketing model built around Independent Business Partners.
Company news also addresses scientific and advisory appointments, regulatory alignment for global wellness products, and international distribution initiatives through subsidiaries and joint ventures in markets such as India and the Gulf Cooperation Council region. Stemtech operates as a Nevada public company that became publicly traded in 2021 after continuing operations under new leadership in 2018.
Stemtech (OTCID: STEK) secured funding to acquire $2.5 million of inventory to protect against supply‑chain interruptions, with purchase orders issued for the first $1.0 million. The move aims to prevent out‑of‑stock issues, support growing retail and e‑commerce channels, and ensure steady supply for Independent Business Partners.
Stemtech (OTC:STEK) launched Stemtech Revolution 2026 on March 18, 2026, expanding its business into a Stemtech BioSciences e-commerce retail channel alongside its existing MLM network. The move establishes a hybrid market model, refreshed branding and a global focus on cellular wellness and consumer accessibility.
Stemtech Corporation (OTC:STEK) launched the Stemtech BioSciences e-commerce retail channel on February 26, 2026, using a Shopify platform to sell plant-based stemceutical products direct to consumers.
The platform aims to broaden retail distribution for nutrition, skin, oral and pet care lines, generate leads for Independent Business Partners, and pilot incentive programs including commission bonuses and potential stock-share rewards.
Stemtech Corporation (OTC: STEK) appointed Dr. Zahooruddin, MBBS (MD), DAASCP to its Life Sciences Advisory Board on February 3, 2026. He joins CSO Dr. Lizette Leos and Dr. Enrique Martinez to support product science and new stemceutical™ development. Dr. Zahooruddin has used Stemtech products since 2010 and leads clinics and wellness ventures servicing patients from over 21 countries. The release reiterates Stemtech's focus on stem cell nutrition and cites a stem cell research market of $4.6B in 2024 with estimates to exceed $30B within five years.
Stemtech (OTCQB:STEK) on January 6, 2026 appointed Dr. Lizette Leos, MD as Chief Scientific Officer.
Dr. Leos has worked with Stemtech since 2017 and will lead global scientific validation, education, and regulatory alignment for Stemtech's recently announced joint ventures in Stemtech HealthSciences India Pvt Ltd and the GCC, and will support Stemtech Asia for business in the People's Republic of China. She holds a medical degree and postgraduate credentials in molecular nutrition and anti-aging medicine and has over 10 years of experience in regenerative medicine, nutrigenomics, and cellular health.
Stemtech emphasizes its all-natural, plant-based stemceuticals and notes its products have been on the market for 20 years.
Stemtech Corporation (OTCQB: STEK) announced a strategic joint venture with Lightway Ventures to establish Stemtech Asia (Hong Kong) to distribute Stemtech products in China, subject to final funding and regulatory approvals.
The JV equity is planned as 51% Stemtech / 49% Lightway with profits split 50/50. Lightway intends to finance the JV and pursue prime placement with a national e-commerce retailer and a leading pharmacy chain, targeting flagship rollouts in Shanghai and Beijing and a quick ramp in 2026. Stemtech will supply products and science, with eventual plans to manufacture in China. The release cites China’s population of ~1.4 billion and a nutraceutical market projection of $109 billion by 2033.
Stemtech Corporation (OTCQB:STEK) and Innoventure Dynamic LLP formed a joint venture, Stemtech HealthSciences India Pvt Ltd, announced October 23, 2025, to enter India and GCC markets with plant-based stemceutical products.
Key specifics: STEK retains 51% ownership, Innoventure 49%, profits split 50/50, and financing provided by India investors. Distribution targets include a 5,500+ outlet organized pharmacy anchor, access to 1.24M+ retail chemists, an initial priority of ~80,000 doors within 24 months, and a focus on e-commerce and professional recommendations in India’s ~$32B nutraceutical market.
Stemtech Corporation (OTCQB:STEK) announced a joint venture with Innoventure Dynamic LLP to form Stemtech HealthSciences India Private Limited (SHIPL) dated October 23, 2025. Stemtech will hold 51% and Innoventure 49% of the JV; India startup funding will be provided entirely by Innoventure.
John W. Meyer will serve as Managing Director for SHIPL. The JV will distribute all Stemtech product lines—stemceuticals, skin care, oral care and pet products—with an eventual plan to manufacture in India and target a population of over 1.4 billion.
Stemtech (OTCQB:STEK) announced on October 20, 2025 that core products are now available for shipment after supply delivery and manufacturing challenges delayed order fulfillment. The company cited tariffs and capital constraints on internationally sourced raw materials as causes of prior backorders.
U.S. backorders are being cleared, inventory for Mexico is being produced and will ship shortly, and shipments to Canada and Ecuador are en route. Management highlighted market demand with a $4.6 billion stem cell market in 2024 and a projected $30 billion market by 2030.
Stemtech Corporation (OTC: STEK) announced an exclusive distribution licensing agreement with Energy International Development Co., Ltd. to sell Stemtech products in Taiwan, R.O.C. on October 9, 2025. The company said products are already manufactured in Taiwan and will be distributed through the licensee's retail networks. Management described the licensing model as a way to generate revenue via licensing fees and manufacturing without the costs of direct operations, while the licensee projects strong growth in the territory.
The announcement emphasizes market expansion, local manufacturing and a low‑overhead licensing strategy to monetize Stemtech's stem cell nutrition products in Taiwan.